594.00GBp-6.60%Mkt Cap: 43.90M $P/E: —Today
Hemogenyx Pharmaceuticals Plc, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of treatments for blood cancer in the United Kingdom and the United States. The company'…
Industry Peers
Biotechnology$130.23BUSDP/E 32.1
$139.84BUSDP/E 32.2
$85.11BUSDP/E 20.4
$69.62BUSD
$61.34BUSDP/E 39.8
$45.95BUSDP/E 19.6
$46.01BUSD
$41.76BUSDP/E 66.2
$35.67BUSDP/E 33.2
$32.46BUSDP/E 42.3
$28.53BUSD
$26.14BUSD
$25.79BUSDP/E 16.2
$20.83BUSDP/E 26.3
$19.26BUSDP/E 26.6
$17.03BUSDP/E 20.0
$16.41BUSD
$13.48BUSDP/E 17.1
$13.42BUSDP/E 187.4
$12.87BUSDP/E 264.5
| Headline | Source | Time |
|---|---|---|
This week | ||
Older | ||
SStock Titan | ||
AACCESS Newswire | ||
SStock Titan | ||
 Hemogenyx Pharmaceuticals Insiders Up UK£1.1m On UK£701.3k Investment Insiders who bought Hemogenyx Pharmaceuticals Plc ( LON:HEMO ) stock lover the last 12 months are probably not as... | ||
Hemogenyx Pharmaceuticals Plc's (LON:HEMO) large institutional owners must be happy as stock continues to impress, up 88% over the past week Key Insights Institutions' substantial holdings in Hemogenyx Pharmaceuticals implies that they have significant... | ||